Valneva SE (NASDAQ:VALN - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $6.71, but opened at $6.93. Valneva shares last traded at $6.78, with a volume of 1,473 shares.
Analyst Ratings Changes
VALN has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Valneva in a report on Monday. Guggenheim decreased their price target on shares of Valneva from $17.00 to $15.00 and set a "buy" rating for the company in a report on Monday, March 24th.
Read Our Latest Research Report on VALN
Valneva Price Performance
The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The stock's 50 day moving average price is $6.81 and its two-hundred day moving average price is $5.61. The stock has a market cap of $485.94 million, a price-to-earnings ratio of -46.00 and a beta of 1.93.
Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The company had revenue of $56.48 million during the quarter, compared to analysts' expectations of $55.64 million. Equities research analysts forecast that Valneva SE will post 0.13 EPS for the current fiscal year.
Institutional Trading of Valneva
An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN increased its stake in Valneva SE (NASDAQ:VALN - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 246,766 shares of the company's stock after acquiring an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned approximately 0.30% of Valneva worth $1,079,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
